Adding a Long‑Acting Muscarinic Antagonist (LAMA) to Dual Therapy in COPD

Guideline Recommendations

The American College of Chest Physicians and the Canadian Thoracic Society give a Grade 2C recommendation that triple therapy (LAMA + ICS + LABA) be preferred over dual therapy for preventing acute COPD exacerbations, emphasizing the importance of reducing exacerbation risk. 1, 2

COPD patients who remain symptomatic or experience ≥2 moderate exacerbations or ≥1 severe exacerbation requiring hospitalization in the previous year despite being on an inhaled corticosteroid/long‑acting β‑agonist (ICS/LABA) regimen should be escalated to triple therapy. 1, 2

Adding a LAMA to an existing ICS/LABA regimen significantly reduces exacerbations, improves lung function, and enhances quality of life compared with continuing dual therapy alone. 1, 2
Both LAMA monotherapy and ICS/LABA therapy independently lower exacerbation risk, and their combination provides an additive benefit. 1, 2
Long‑acting muscarinic antagonists are superior to short‑acting muscarinic antagonists for preventing moderate‑to‑severe COPD exacerbations (Grade 1A). 3

Separate LAMA inhaler: Adding umeclidinium 62.5 µg (Incruse Ellipta) or tiotropium 18 µg (HandiHaler/Respimat) once daily to the current ICS/LABA inhaler is an evidence‑supported approach to achieve triple therapy. 1, 3

Pneumonia risk is increased with inhaled corticosteroid‑containing regimens, especially in older adults and those with a prior history of pneumonia; regular monitoring is advised. 1, 2
Clinicians should watch for oral candidiasis, hoarseness, dysphonia, and upper respiratory tract infections associated with ICS use. 1, 2

Do not add a short‑acting muscarinic antagonist (e.g., ipratropium) as maintenance therapy when a long‑acting option is available, as LAMA provides superior efficacy. 3
Do not increase the inhaled corticosteroid dose alone without adding a LAMA; escalating the steroid dose without a LAMA is not recommended for COPD management. 1, 2

The American Thoracic Society recommends triple therapy, like Trelegy, for patients with persistent moderate to severe dyspnea despite dual therapy, and for patients at high risk of COPD exacerbations 4
The European Respiratory Society suggests that single inhaler triple therapy (SITT) may reduce mortality in individuals with moderate-severe disease compared to dual therapy options 4

The European Respiratory Journal notes that Trelegy uses the Ellipta inhaler device, while Wixela uses the Inhub device, similar to Advair Diskus 5
The European Respiratory Journal also states that Trelegy is administered once daily, while Wixela is typically administered twice daily 5

The European Respiratory Review emphasizes the importance of patient education when switching between these medications, highlighting the differences in devices, dosing schedules, and expected effects 6

The Global Initiative for Chronic Obstructive Lung Disease (GOLD), Canadian Thoracic Society, American Thoracic Society, and European Respiratory Society recommend single inhaler triple therapy (SITT) for COPD patients with moderate-severe disease, as it may reduce mortality compared to dual therapy options 7

Anoro Ellipta (umeclidinium/vilanterol 62.5/25 mcg) is superior to Breo for patients where ICS risks outweigh benefits, those with primarily obstructive symptoms without inflammatory exacerbation phenotype, and patients experiencing ICS-related adverse effects on Breo 7

The combination therapy recommendations come from multiple high-quality guidelines, but a Cochrane review noted that the relative efficacy and safety of combination inhalers remains somewhat uncertain due to missing outcome data in current studies 8